ArticleClinical microbiology reviews1996
Epidemiology of nosocomial fungal infections.
Article in Clinical microbiology reviews, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed.
- Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2008Trial
- Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.Antimicrobial agents and chemotherapy · 2004Trial
- Efficacy of parenteral nutrition supplemented with glutamine dipeptide to decrease hospital infections in critically ill surgical patients.JPEN. Journal of parenteral and enteral nutritionTrial
- Article
- Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review.Clinical pharmacokinetics · 2024Review
- Candida albicans and Antifungal Peptides.Infectious diseases and therapy · 2023Article
- Transforming medical device biofilm control with surface treatment using microfabrication techniques.PloS one · 2023Article
- Candida albicans Infections: a novel porcine wound model to evaluate treatment efficacy.BMC microbiology · 2022Article
- Growth ofJournal of fungi (Basel, Switzerland) · 2022Review
- The Antimicrobial Activity of Omiganan Alone and In Combination againstAntibiotics (Basel, Switzerland) · 2021Article
- Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.Journal of fungi (Basel, Switzerland) · 2021Review
- Understanding Human Microbiota Offers Novel and Promising Therapeutic Options againstPathogens (Basel, Switzerland) · 2021Review
- Review
- Oral Candida Mannan Concentrations Correlate with Symptoms/Signs of Ill Health and the Immune Status.Mycopathologia · 2020Article
- Potency of gastrointestinal colonization and virulence of Candida auris in a murine endogenous candidiasis.PloS one · 2020Article
- Relationship Between the Quantity of Oral Candida and Systemic Condition/Diseases of the Host: Oral Candida Increases with Advancing Age and Anemia.Mycopathologia · 2019Article
- Genome-resolved metagenomics of eukaryotic populations during early colonization of premature infants and in hospital rooms.Microbiome · 2019Article
- Effect of resveratrol and Regrapex-R-forte on Trichosporon cutaneum biofilm.Folia microbiologica · 2019Article
- Frequency Distribution of Keratinophilic Dermatophyte Fungi from the Soil of Different Zones in Isfahan Using Morphological and Molecular Methods.Advanced biomedical research · 2019Article
- Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide.Turkish journal of pharmaceutical sciences · 2018Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper briefly reviews the current knowledge of the epidemiology and modes of transmission of nosocomial fungal infections and some of the therapeutic options for treating these diseases. In the mid-1980s, many institutions reported that fungi were common pathogens in nosocomial infections. Most, if not all, hospitals care for patients at risk for nosocomial fungal infections. The proportion in all nosocomial infections reportedly caused by Candida spp. increased from 2% in 1980 to 5% in 1986 to 1989. Numerous studies have identified common risk factors for acquiring these infections, most of which are very common among hospitalized patients; some factors act primarily by inducing immunosuppression (e.g., corticosteroids, chemotherapy, malnutrition, malignancy, and neutropenia), while others primarily provide a route of infection (e.g., extensive burns, indwelling catheter), and some act in combination. Non-albicans Candida spp., including fluconazole-resistant C. krusei and Torulopsis (C.) glabrata, have become more common pathogens. Newer molecular typing techniques can assist in the determination of a common source of infection caused by several fungal pathogens. Continued epidemiologic and laboratory research is needed to better characterize these pathogens and allow for improved diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.